deltatrials
Completed PHASE3 INTERVENTIONAL 3-arm NCT02481830

Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer (CheckMate331)

An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First Line Chemotherapy (CheckMate 331: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 331)

Sponsor: Bristol-Myers Squibb

Conditions Lung Cancer
Interventions Amrubicin Nivolumab Topotecan
Updated 32 times since 2017 Last updated: Jul 19, 2023 Started: Sep 14, 2015 Primary completion: Aug 17, 2018 Completion: Aug 30, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02481830, this PHASE3 trial focuses on Lung Cancer and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 32 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Apr 2017 · 31 days · monthly snapshot~Apr 2017 – ~May 2017 · 30 days · monthly snapshot~May 2017 – ~Nov 2017 · 6 months · monthly snapshot~Nov 2017 – ~Feb 2018 · 3 months · monthly snapshot~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~Apr 2018 · 31 days · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Feb 2019 · 2 months · monthly snapshot~Feb 2019 – ~May 2019 · 3 months · monthly snapshot~May 2019 – ~Feb 2020 · 9 months · monthly snapshot~Feb 2020 – ~Apr 2020 · 2 months · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jul 2020 · 2 months · monthly snapshot~Jul 2020 – ~Sep 2020 · 2 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Nov 2021 · 10 months · monthly snapshot~Nov 2021 – ~Mar 2022 · 4 months · monthly snapshot~Mar 2022 – ~May 2022 · 2 months · monthly snapshot~May 2022 – ~Oct 2022 · 5 months · monthly snapshot~Oct 2022 – ~Aug 2023 · 10 months · monthly snapshot~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

32 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Aug 2023 — Jul 2024 [monthly]

    Completed PHASE3

  5. Oct 2022 — Aug 2023 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

▶ Show 27 earlier versions

  1. May 2022 — Oct 2022 [monthly]

    Active Not Recruiting PHASE3

  2. Mar 2022 — May 2022 [monthly]

    Active Not Recruiting PHASE3

  3. Nov 2021 — Mar 2022 [monthly]

    Active Not Recruiting PHASE3

  4. Jan 2021 — Nov 2021 [monthly]

    Active Not Recruiting PHASE3

  5. Sep 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  6. Jul 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE3

  7. May 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE3

  8. Apr 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE3

  9. Feb 2020 — Apr 2020 [monthly]

    Active Not Recruiting PHASE3

  10. May 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE3

  11. Feb 2019 — May 2019 [monthly]

    Active Not Recruiting PHASE3

  12. Dec 2018 — Feb 2019 [monthly]

    Active Not Recruiting PHASE3

  13. Nov 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE3

  14. Oct 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE3

  15. Sep 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE3

  16. Aug 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE3

  17. Jul 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE3

  18. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE3

  19. Apr 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  20. Mar 2018 — Apr 2018 [monthly]

    Active Not Recruiting PHASE3

  21. Feb 2018 — Mar 2018 [monthly]

    Active Not Recruiting PHASE3

  22. Nov 2017 — Feb 2018 [monthly]

    Active Not Recruiting PHASE3

  23. May 2017 — Nov 2017 [monthly]

    Active Not Recruiting PHASE3

  24. Apr 2017 — May 2017 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  25. Mar 2017 — Apr 2017 [monthly]

    Recruiting PHASE3

    Status: Active Not Recruiting → Recruiting

  26. Feb 2017 — Mar 2017 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  27. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Sep 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • Ono Pharmaceutical Co. Ltd
Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akashi-shi, Japan , Athens, Greece , Atlanta, United States , Bamberg, Germany , Barcelona, Spain , Barretos, Brazil , Basel, Switzerland , Beersheba, Israel , Beijing, China , Bergen, Norway and 124 more locations